EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2 V617F ‐Positive Myeloproliferative Neoplasms

Guangshuai Teng, Ke Shang, Yuhui Zhang, Yifan Duan, Chenxiao Du, Yan Wang, Yanqi Li, Huiqin Zhang, Lan Peng, Xiaojing Wei, Gary Tse, Yuan Zhou iD und 5 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Guangshuai Teng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China. Hauptthemen laut MEDLINE: Janus Kinase 2, Atrial Fibrillation, Myeloproliferative Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Municipal Education Commission Scientific Research Plan Project of Tianjin, National Natural Science Foundation of China, Haihe Laboratory of Cell Ecosystem Innovation Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The incidence, outcomes and risk factors for AF in the JAK2 V617F ‐positive MPN patients are still unknown.

Methods

The clinical profiles of patients with JAK2 V617F ‐positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk factors of AF, thereby developing a risk prediction model.

Results

A total of 439 patients were included (age 57 [12–87] years; 51.3% male). AF was associated with higher risks of stroke ( p = 0.036, HR = 1.987, 95% CI 1.047–3.772) and mortality ( p < 0.001, HR = 3.857, 95% CI 1.836–8.103). Multivariable Cox regression showed that TET2 mutation ( p = 0.042, HR = 4.361, 95% CI 1.053–18.056) and increased IL‐1β ( p = 0.012, HR = 5.476, 95% CI 1.547–28.123) were significant risk factors for AF in patients with JAK2 V617F ‐positive MPN. Nomograms were constructed, allowing patients to be categorized into high‐ and low‐risk groups. The 10‐year AF‐free survival rate was significantly lower in the high‐risk group (62% vs. 91.7%; log‐rank test: p = 0.002). The validation cohort confirmed that the survival without AF in the high‐risk group was significantly worse than that in the low‐risk group. The use of either interferon‐α or ruxolitinib, was associated with longer AF‐free survival in the high‐risk group ( p < 0.05).

Conclusion

AF was significantly associated with higher risks of stroke and mortality. TET2 mutation and increased IL‐1β were independent risk factors of AF in patients with JAK2 V617F ‐positive MPN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2Atrial FibrillationMyeloproliferative DisordersHumansMaleFemaleMiddle AgedAgedRisk FactorsAged, 80 and overIncidenceAdultRetrospective StudiesAdolescentYoung AdultMutationDioxygenasesDNA-Binding ProteinsPrognosis

Stichwörter der Autor:innen

JAK2 V617Fatrial fibrillationcytokinesgene mutationmyeloproliferative neoplasms

Substanzen

Janus Kinase 2JAK2 protein, humanDioxygenasesTET2 protein, humanDNA-Binding Proteins

Autor:innen und Institutionen

  • Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Department of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.
  • Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin, China.
  • Tianjin Institute of Cardiology, Tianjin, China.
  • School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China.
  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…

ORCID-Profile: Yuan Zhou, Tong Liu, Minghui Duan, Jie Bai

Förderung

  • Municipal Education Commission Scientific Research Plan Project of Tianjin
  • National Natural Science Foundation of China
  • Haihe Laboratory of Cell Ecosystem Innovation Fund

Zitieren

APA

Teng, G., Shang, K., Zhang, Y., Duan, Y., Du, C., Wang, Y., Li, Y., Zhang, H., Peng, L., Wei, X., Tse, G., Zhou, Y., Lip, G. Y. H., Liu, T., Yang, W., Duan, M., & Bai, J. (2025). Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2 V617F ‐Positive Myeloproliferative Neoplasms. Cancer Medicine. https://doi.org/10.1002/cam4.71015

Vancouver

Teng G, Shang K, Zhang Y, Duan Y, Du C, Wang Y, et al. Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2 V617F ‐Positive Myeloproliferative Neoplasms. Cancer Medicine. 2025. doi:10.1002/cam4.71015

BibTeX
@article{Teng2025,
  author = {Teng, Guangshuai and Shang, Ke and Zhang, Yuhui and Duan, Yifan and Du, Chenxiao and Wang, Yan and Li, Yanqi and Zhang, Huiqin and Peng, Lan and Wei, Xiaojing and Tse, Gary and Zhou, Yuan and Lip, Gregory Y H and Liu, Tong and Yang, Wei and Duan, Minghui and Bai, Jie},
  title = {Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2 V617F ‐Positive Myeloproliferative Neoplasms},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71015}
}
Kostenlos starten →